-
公开(公告)号：US20130330346A1
公开(公告)日：2013-12-12
申请号：US13886530
申请日：2013-05-03
申请人： Zarin Brown , Michelle Bradley , Steven John Charlton , Gino Anselmus Van Heeke , Karen Cromie , Bruno Dombrecht , Soren Steffensen , Judith Baumeister , Marie-Paule Bouche , Carlo Boutton , Marie-Ange Buyse , Veerle Snoeck , Stephanie Staelens
发明人： Zarin Brown , Michelle Bradley , Steven John Charlton , Gino Anselmus Van Heeke , Karen Cromie , Bruno Dombrecht , Soren Steffensen , Judith Baumeister , Marie-Paule Bouche , Carlo Boutton , Marie-Ange Buyse , Veerle Snoeck , Stephanie Staelens
IPC分类号： C07K16/46
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/468 , C07K2317/22 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
摘要： The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
摘要翻译： 本发明涉及针对或特异性结合趋化因子受体CXCR2的多肽，特别涉及能够调节CXCR2信号转导的多肽。 本发明还涉及能够表达本发明多肽的核酸，载体和宿主细胞，包含多肽的药物组合物以及用于治疗涉及CXCR2异常功能的疾病的所述多肽和组合物的用途。
-
公开(公告)号：US09127067B2
公开(公告)日：2015-09-08
申请号：US14065679
申请日：2013-10-29
申请人： Michelle Bradley , Steven John Charlton , Karen Cromie , Bruno Dombrecht , Soren Steffensen , Gino Anselmus Van Heeke
发明人： Zarin Brown , Michelle Bradley , Steven John Charlton , Karen Cromie , Bruno Dombrecht , Soren Steffensen , Gino Anselmus Van Heeke
IPC分类号： A61K39/395 , C07K16/28 , C07K16/46
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/569 , C07K2317/626 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
摘要翻译： 本发明涉及针对或特异性结合趋化因子受体CXCR2的多肽，特别涉及能够调节CXCR2信号转导的多肽。 本发明还涉及能够表达本发明多肽的核酸，载体和宿主细胞，包含多肽的药物组合物以及用于治疗涉及CXCR2异常功能的疾病的所述多肽和组合物的用途。
-
公开(公告)号：US08591896B2
公开(公告)日：2013-11-26
申请号：US13290175
申请日：2011-11-07
申请人： Michelle Bradley , Zarin Brown , Steven John Charlton , Karen Cromie , Bruno Dombrecht , Soren Steffensen , Gino Van Heeke
发明人： Michelle Bradley , Zarin Brown , Steven John Charlton , Karen Cromie , Bruno Dombrecht , Soren Steffensen , Gino Van Heeke
IPC分类号： A61K39/395 , C07K16/46 , C12N15/13 , C12N15/62 , C12N5/10
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/569 , C07K2317/626 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
-
公开(公告)号：US20180009888A9
公开(公告)日：2018-01-11
申请号：US14128681
申请日：2012-06-25
申请人： Judith Baumeister , Marie-Paule Lucienne Armanda Bouche , Carlo Boutton , Marie-Ange Buyse , Veerle Snoeck , Stephanie Staelens , Bruno Dombrecht , Peter Schotte , Cedric Jozef Neotere Ververken , Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Tinneke Denayer
发明人： Judith Baumeister , Marie-Paule Lucienne Armanda Bouche , Carlo Boutton , Marie-Ange Buyse , Veerle Snoeck , Stephanie Staelens , Bruno Dombrecht , Peter Schotte , Cedric Jozef Neotere Ververken , Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Tinneke Denayer
CPC分类号： C07K16/28 , C07K16/00 , C07K16/4283 , C07K2317/22 , C07K2317/569 , C07K2317/94 , C07K2319/30 , G01N33/6854
摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
-
公开(公告)号：US08703135B2
公开(公告)日：2014-04-22
申请号：US13435567
申请日：2012-03-30
申请人： Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Cedric Jozef Neotere Ververken , Tinneke Denayer
发明人： Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Cedric Jozef Neotere Ververken , Tinneke Denayer
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , C07K16/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/18 , C07K2317/22 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12Q1/6876 , G01N33/53
摘要： The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
摘要翻译： 本发明涉及与可能与VEGF和/或EGFR组合的c-Met相关的生物学材料，更具体地涉及编码这些多肽的多肽，核酸; 制备这种多肽的方法; 以宿主表达或能够表达这种多肽的细胞; 组合物，特别是涉及用于预防，治疗或诊断目的的包含这种多肽的药物组合物。 还描述和提供了用于评估患者对c-Met治疗的反应性的方法和试剂盒。
-
公开(公告)号：US20120244164A1
公开(公告)日：2012-09-27
申请号：US13435567
申请日：2012-03-30
申请人： Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Cedric Jozef Neotere Ververken , Tinneke Denayer
发明人： Gerald Beste , Guy Hermans , Soren Steffensen , Alexander Szyroki , Cedric Jozef Neotere Ververken , Tinneke Denayer
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/18 , C07K2317/22 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12Q1/6876 , G01N33/53
摘要： The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
摘要翻译： 本发明涉及与可能与VEGF和/或EGFR组合的c-Met相关的生物学材料，更具体地涉及编码这些多肽的多肽，核酸; 制备这种多肽的方法; 以宿主表达或能够表达这种多肽的细胞; 组合物，特别是涉及用于预防，治疗或诊断目的的包含这种多肽的药物组合物。 还描述和提供了用于评估患者对c-Met治疗的反应性的方法和试剂盒。
-
7.发明申请AMINO ACID SEQUENCES DIRECTED AGAINST GROWTH FACTOR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH GROWTH FACTORS AND THEIR RECEPTORS 审中-公开指导生长因子受体的氨基酸序列和包含与治疗与生长因子及其受体相关的疾病和疾病相同的氨基酸公开(公告)号：US20110282033A1
公开(公告)日：2011-11-17
申请号：US12600023
申请日：2008-05-23
申请人： Maria Gonzalez Pajuelo , Michael John Scott Saunders , Johannes Joseph Wilhelmus De Haard , Edward Dolk , Soren Steffensen
发明人： Maria Gonzalez Pajuelo , Michael John Scott Saunders , Johannes Joseph Wilhelmus De Haard , Edward Dolk , Soren Steffensen
CPC分类号： C07K16/2863 , C07K2317/22 , C07K2317/569 , C07K2317/76 , C07K2319/32
摘要： The present invention relates to amino acid sequences that are directed against receptors for growth factors, compounds comprising such sequences, as well as nucleic acid sequences encoding the same. In one embodiment the invention relates to amino acid sequences that bind to a receptor tyrosine kinase. The receptor tyrosine kinase and/or growth factor receptor may be of human origin. In one embodiment the amino acid sequences are Nanobodies™.
摘要翻译： 本发明涉及针对生长因子受体的氨基酸序列，包含该序列的化合物以及编码该氨基酸序列的核酸序列。 在一个实施方案中，本发明涉及结合受体酪氨酸激酶的氨基酸序列。 受体酪氨酸激酶和/或生长因子受体可能是人类来源的。 在一个实施方案中，氨基酸序列是纳米抗体TM。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.06 秒)
